ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

Rhea-AI Summary

ESSA Pharma Inc. announces results of Annual General Meeting of Shareholders, re-elects board members and approves key resolutions.

SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024  /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting").

At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin M. Berger, Scott Requadt, Marella Thorell, Alex Martin, Sandy Zweifach, Philip Kantoff and Lauren Merendino to serve in office until the next annual meeting or until their successors are duly elected or appointed. Detailed results of the voting in respect of the election of directors are as follows:

Nominee	Votes For	% Votes For	Votes Withheld	% Votes Withheld
David R. Parkinson	29,947,985	99.73 %	81,989	0.27 %
Richard MGlickman	29,948,035	99.73 %	81,939	0.27 %
Gary Sollis	29,945,788	99.72 %	84,186	0.28 %
Franklin M. Berger	29,937,249	99.69 %	92,725	0.31 %
Scott Requadt	29,947,985	99.73 %	81,989	0.27 %
MarellaThorell	23,840,414	79.39 %	6,189,560	20.61 %
Alex Martin	30,014,431	99.95 %	15,543	0.05 %
Sandy Zweifach	30,013,358	99.94 %	16,616	0.06 %
Philip Kantoff	30,014,381	99.95 %	15,593	0.05 %
Lauren Merendino	30,015,635	99.95 %	14,339	0.05 %

At the Meeting, the Shareholders also approved: (i) the re-appointment of Davidson & Company LLP, Chartered Professional Accountants, as auditors of the Company; (ii) an amendment to the Company's omnibus incentive plan (as amended, the "Amended Omnibus Plan") to increase the number of common shares of the Company reserved and available for issuance under the Amended Omnibus Plan; and (iii) on a non-binding advisory basis, the compensation of the Company's named executive officers.

Contact Information:

David Wood
Chief Financial Officer, ESSA Pharma Inc.
T: 778-331-0962
E: dwood@essapharma.com

About ESSA Pharma Inc.

ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com and follow us on Twitter under @ESSAPharma.

View original content:https://www.prnewswire.com/news-releases/essa-pharma-inc-reports-results-of-annual-general-meeting-of-shareholders-302083628.html

SOURCE ESSA Pharma Inc

FAQ

Who are the re-elected board members of ESSA Pharma Inc.?

The re-elected board members of ESSA Pharma Inc. are David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin M. Berger, Scott Requadt, Marella Thorell, Alex Martin, Sandy Zweifach, Philip Kantoff, and Lauren Merendino.

What percentage of votes were in favor of re-electing David R. Parkinson?

99.73% of votes were in favor of re-electing David R. Parkinson.

What resolutions were approved at the Annual General Meeting of Shareholders?

Resolutions approved at the meeting include re-appointment of auditors, amendment to the omnibus incentive plan, and non-binding advisory approval of executive officer compensation.

Who is the Chief Financial Officer of ESSA Pharma Inc.?

David Wood is the Chief Financial Officer of ESSA Pharma Inc.